Vycor Medical, Inc. (OTCQB: VYCO) reported financial results for the three months ended March 31, 2026, showing revenue growth and a return to operating profitability. The company operates through two units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgeons, and NovaVision®, which offers vision rehabilitation therapies for patients recovering from stroke or brain injury.
For the quarter, total revenue was $458,540, a 5% increase from $436,378 in the same period of 2025. The Vycor Medical division generated $440,441, up 5% year-over-year, with most of the growth coming from international markets, a key strategic focus. Gross margin remained strong at 82% for the division. NovaVision contributed $18,099 in revenue, with a gross margin of 89%. On a GAAP basis, the company reported an operating profit of $45,808, compared to an operating loss of $(12,806) in the prior year period. Non-GAAP operating profit was $59,788, up from $20,388, reflecting improved cost control as non-GAAP cash operating expenses fell to $315,365 from $338,146.
The company also highlighted two new peer-reviewed studies published in 2026 on the VBAS, bringing the total to 52 published clinical papers. One case study focused on a complex pediatric tumor, emphasizing the effectiveness of integrating neuro-navigation systems with VBAS as “a paramount strategy for the surgical resection” of such lesions. The second, a retrospective study of 23 patients undergoing tumor resection, compared outcomes using VBAS versus traditional blade retractors. The study reported significantly fewer new neurological deficits at follow-up for the tubular retractor group, implying safer tumor resection using VBAS. These findings could influence neurosurgeons’ adoption of minimally invasive techniques, potentially reducing post-surgical complications and recovery times for patients.
Despite the operating profit, the company reported a net loss available to common stockholders of $(142,077), primarily due to preferred stock dividends of $162,185. On a non-GAAP basis, net loss was $(128,097). The weighted average shares outstanding remained flat at 33,372,796. Vycor Medical continues to invest in its NovaVision division, which remains in development but offers the only FDA-cleared Visual Restoration Therapy for vision rehabilitation after neurological damage, supported by a 296-patient study. For more information, visit Vycor Medical, Vycor VBAS, or NovaVision.
